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ABSTRACT
Introduction: Hypertrophic cardiomyopathy
(HCM), a complex myocardial disorder with
an autosomal dominant genetic pattern and
prevalence of 1:500, is the most frequent
cause of sudden death in apparently healthy
young people. The benefits of gene-based
diagnosis of HCME for both basic research
and clinical medicine are limited by the
considerable costs of current genetic testing
due to the large number of genes and muta-
tions involved in this pathology. However,
coupling two high-throughput techniques –
mass spectrometry genotyping (MSG) and
high resolution melting (HRM) – is an
encouraging new strategy for HCM diagno-
sis. Our aim was to evaluate the diagnostic
efficacy of both techniques in this pathology
by studying 13 individuals with a clinical
phenotype of HCM. Methods: Peripheral
blood samples were collected from: (i) seven
subjects with a clinical diagnosis of HCM,
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RESUMO
A Miocardiopatia Hipertrófica (MH), uma
doença genética complexa do miocárdio com
um padrão de transmissão autossómica
dominante e prevalência de 1:500, é a forma
mais frequente de morte súbita em jovens
aparentemente saudáveis. Os benefícios de
um diagnóstico baseado nos genes
associados a MH, adequado à investigação
básica e à prática clínica, estão, no entanto,
limitados pelos consideráveis custos das
estratégias actuais de diagnóstico genético,
baseadas em sequenciação automática,
devido ao elevado número de genes e
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all bearing known mutations previously
identified by dideoxy sequencing and thus
being used as blinded samples (sample type
1); (ii) one individual with a clinical diagno-
sis of HCM negative for mutations after
dideoxy sequencing of the five most com-
mon HCM genes, MYH7, MYBPC3, TNNI3,
TNNT2 and MYL2 (sample type 2); and (iii)
five individuals individual with a clinical
diagnosis of HCM who had not previously
been genetically studied (sample type 3).
Results: The 13 samples were analyzed by
MSG for 534 known mutations in 32 genes
associated with HCM phenotypes and for all
coding regions and exon-intron boundaries
of the same HCM genes by HRM. The 32
studied genes include the most frequent
HCM-associated sarcomere genes, as well
as 27 genes with lower reported HCM phe-
notype association. This coupled genotyping
strategy enabled us to identify a c.128delC
(p.A43Vfs165) frame-shift mutation in the
CSRP3 gene, a gene not usually studied in
current HCM genetics. The heterozygous
CSRP3 mutation was found in two patients
(sample types 2 and 3) aged 50 and 52
years, respectively, both with diffuse left
ventricular hypertrophy. Furthermore, this
coupled strategy enabled us to find a novel
mutation, c.817C>T (p.Arg273Cys), in
MYBPC3 in an individual from sample type
3, subsequently confirmed by dideoxy
sequencing. This novel mutation in
MYBPC3, not present in 200 chromosomes
from 200 healthy individuals, affects a
codon known to harbor an HCM-causing
mutation – p.Arg253His. Conclusion: In
conclusion, in the cohort used in this work
coupling two technologies, MSG and HRM,
with high sensitivity and low false positive
results, enabled rapid, innovative and low-
cost genotyping of HCM patients, which
may in the short term be suitable for accu-
rate genetic diagnosis of HCM. 
consideramos que a conjugação de duas
técnicas de elevada resolução –
Genotipagem por Espectrometria de Massa
(GEM) e Desnaturação de Alta Resolução
(DAR) – tem demonstrado ser uma
estratégia encorajante para o diagnóstico de
MH. Foi nosso objectivo avaliar a eficácia
diagnóstica destas duas técnicas no âmbito
desta patologia, estudando 13 indivíduos
com fenótipo de MH. Neste sentido, foram
colhidas amostras de sangue periférico de:
(i) sete indivíduos clinicamente
diagnosticados com MH, todos com
mutações previamente identificadas por
sequenciação automática, e actuando como
amostras blinded (“amostra tipo 1”); (ii) um
indivíduo clinicamente diagnosticado com
MH sem mutações identificadas após
sequenciação dos 5 principais genes
associados a MH, MYH7, MYBPC3, TNNI3,
TNNT2 e MYL2 (“amostra tipo 2”); e (iii)
cinco indivíduos clinicamente
diagnosticados com MH sem estudo
genético prévio (“amostra tipo 3”). As 13
amostras foram analisadas por GEM para
534 mutações conhecidas em 32 genes
associados a um fenótipo de MH e para
todas as regiões codificantes e fronteiras
exão/intrão dos mesmos genes por DAR.
Estes 32 genes estudados incluem os 5
genes mais frequentemente associados a
MH e outros 27 genes reportados como
associados a MH numa menor frequência.
Esta estratégia permitiu-nos identificar uma
mutação c.128delC (p. A43Vfs165) que
origina uma alteração na grelha de leitura
da proteína codificada pelo gene CSRP3,
um gene usualmente não analisado pela
estratégia corrente de diagnóstico genético.
Esta mutação em heterozigotia no gene
CSRP3 foi encontrada em dois doentes
(amostra tipo 2 e 3) com 50 e 52 anos
respectivamente, e que apresentavam
hipertrofia ventricular esquerda difusa. Esta
estratégia permitiu-nos ainda identificar
uma nova alteração c. C>T817
(p.Arg273Cys) no gene MYBPC3 num
indivíduo da amostra tipo 3 que foi
posteriormente confirmada por
sequenciação. Esta nova alteração no gene
INTRODUCTION
Cardiomyopathies are associated with my-ocardial dysfunction which varies from an
asymptomatic course to heart failure (HF) (1, 2, 3).
Hypertrophic cardiomyopathy (HCM), an
autosomal dominant genetic disease which
may afflict as many as 1 in 500 subjects and
is an important risk factor for sudden death
(SD) or HF disability at any age, is character-
ized by a hypertrophied, non-dilated left ven-
tricle (LV), myocyte disarray and interstitial
fibrosis (4). HCM is the most frequent cause of
SD in otherwise healthy young people; it may
in fact be the only clinical manifestation of the
disease. Genetic diagnosis is important in all
patients with suspected HCM for several rea-
sons: counseling on professional and/or
leisure activities (particularly in young people
with a family history or familial SD); for genet-
ic counseling (in the belief that certain muta-
tions may be more dangerous than others);
and, in general, to facilitate genetic diagnosis
in family members once a mutation has been
identified in the index patient(1, 2, 3). 
Mutations in genes coding for myofilament
contractile proteins of the cardiac sarcomere,
including MYBPC3, MYH7, TNNT2, TNNI3
and MYL2, represent the most common genet-
ic subtype of HCM, with 30% to 65% preva-
lence in various cohort studies, and HCM has
accordingly been defined as a disease of the
sarcomere (Figure 1)(5). Age dependency and
absence of evident and unequivocal symptoms
lead to a high probability of the condition
being detected only after a sudden death (SD)
event. Due to the large number of HCM-asso-
ciated genes and the allelic heterogeneity of
this disease, genetic screening techniques
such as single strand conformational polymor-
phism (SSCP), denaturing gradient gel elec-
trophoresis (DGGE) and denaturing high pres-
sure liquid chromatography (dHPLC) are
expensive and time-consuming. Automated
dideoxy sequencing (AS) of the most frequent
mutated HCM genes (Table I – bold), the cur-
rent gold standard genetic diagnosis test for
HCM in Portugal, has low throughput, high
cost (€350/gene) and poor sensitivity for
detecting copy number variations (CNVs) or
insertions/deletions (indels) and does not
include genes that code for other proteins
related to myocardium contraction such as the
Z-band (Figure 1). The Z band is critical for 9
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MYBPC3, ausente em 200 cromossomas de
indivíduos saudáveis, afecta um codão cuja
mutação foi já associada a MH –
p.Arg253His. Em conclusão, a conjugação
de duas tecnologias, GEM e DAR, de
elevada sensibilidade e baixo nível de
resultados falsos positivos permitiu, na
amostragem utilizada neste trabalho, uma
genotipagem rápida, inovadora e de baixo
custo em doentes com MH, podendo vir a
tornar-se a curto prazo numa metodologia
apropriada para o diagnóstico genético de
MH.
Palavras-Chave: 
Miocardiopatia hipertrófica; Diagnóstico genético;
Espectrometria de Massa por Arrays; Desnaturação de
Alta Resolução; Proteínas sarcoméricas; gene CSRP3;
Proteínas do disco Z
Key words
Hypertrophic cardiomyopathy;
Gene-based diagnosis; Array-based mass spectrome-
try; High resolution melting; Sarcomere proteins;
CSRP3 gene; Z-disc proteins
cytoarchitecture and is involved in mechanosen-
sory cardiomyocyte signaling (7). It is composed
of titin (TTN), teletonin (TCAP) and muscle Z
protein (CSRP3). Remarkably, mutations in
all of these genes have been found to cause
HCM.
The fact that in more than one third of
proband analysis no mutation is found(8) fur-
ther reduces the cost-effectiveness of the cur-
rent genetic test, and underlines the need to
seek novel genes/mutations that enable reli-
able genetic diagnosis. The existence of more
10
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Figure 1. Sarcomere-related structures(6).
than 646 HCM phenotype-associated muta-
tions in 32 different genes (Table I) makes full
molecular testing by AS unacceptably slow
and expensive, prompting DNA microarrays
as an alternative technique (9-11). Our group is
currently validating iPLEX mass spectrometry
genotyping (MSG) and high resolution melting
(HRM) to improve HCM-gene based diagno-
sis. In contrast with AS genetic testing, high-
throughput techniques such as MSG and
HRM scanning allow rapid and cost-effective
testing for a large number of different muta-
tions simultaneously. MSG involves multiplex
primary PCR using outer primers that flank
HCM mutation sites followed by a homoge-
neous mass extend (hME) reaction with multi-
ple single inner primers that together generate
fragments of different mass specific for each
genotype (iPLEX). To date, 534 mutations in
32 HCM-associated genes have been validat-
ed by our group (Table I) and a newly designed
chip with 646 known mutations in 32 genes is
being implemented. HRM is a high-through-
put gene variation scanning technique that
relies on the differential melting properties of
sequences that vary in at least one nucleotide.
For this reason it is used to identify novel
mutations within samples. An advantage of
MSG in comparison with other DNA microar-
ray techniques(10) is its capacity for detecting
indels(10). Nevertheless, MSG is ineffective for
detecting novel mutations (11), making our cou-
pled strategy using both MSG and HRM more
effective. The two techniques have overall
costs of €50 and €350, respectively. We test-
ed the validity of the MSG-HRM coupled
strategy due to its potential for significantly
increasing the throughput and speed of muta-
tion detection, not to mention its promising
value in association studies. This would apply
to both known and unknown mutations in
HCM patients or others, thus allowing analy-
sis of genes specifically or randomly within a
population or case study. Through this dual
approach genes not previously studied by AS,
such as those coding for Z-band proteins, will
also be evaluated for mutations. The aim of
this work was to develop new low-cost, accu-
rate, gene-based diagnosis that will contribute
to the understanding of the genetic basis of
disease in specific populations. This approach
has the potential to significantly increase our
understanding about HCM development and
recognition, being a major support in the dif-
ficult clinical diagnosis of complex diseases. 
METHODS
Peripheral blood was collected from 13
white patients (Portuguese) with a diagnosis of
familial HCM, and from 100 healthy subjects
(controls). Diagnosis was established on clini-
cal, electrocardiographic (ECG) and echocar-
diographic (echo) grounds. The ECG/echo cri-
teria have been previously discussed and pub-
lished elsewhere(13). Blood samples from HCM
patients were divided into three groups: (i)
seven blinded samples from patients with
known mutations (detected previously by AS
of the five most common HCM genes
[MYBPC3, MYH7, TNNT2, TNNI3 and MYL2]
in a reference genetic diagnostic laboratory of
reference)(12), (ii) a sample negative for muta-
tions in the above HCM genes, and (iii) five
samples not previously studied. The study was
approved by the Ethics Committee of
Faculdade de Medicina de Lisboa and all
patients gave their written informed consent
for genetic analysis. 
DNA was extracted from the blood samples
using a Blood DNA kit (Roche Diagnostics).
All DNA samples were analyzed for 534
HCM-causing mutations (Human Genome
Mutation Database http://www.hgmd.org; and
the Harvard Sarcomere Protein Gene
Mutation Database http://genepath.med.har-
vard.edu/~seidman/cg3/) in 32 HCM genes
(Table I). Genotyping was performed using the
iPLEX MassARRAY matrix-assisted laser
desorption/ionization time-of-flight (MALDI-
TOF) method (Sequenom GmbH, Germany).
The MSG system, based on the single-base
extension of an extend primer into the region
of DNA variation, allows the detection of
insertions, deletions, and single-base substi-
tutions in amplified DNA at multiplex levels
of up to 36 DNA variants (Figure 2). The
11
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Figure 2. The MassEXTEND iPLEX reaction. An illustration of the genotype reaction of a C-to-G SNP(15).
extend primer is designed to hybridize adja-
cent to the variant being assayed and is
extended by one of four mass-modified termi-
nator molecules into the site of the nucleotide
variation (mutation). The primer extension
products are analyzed using MALDI-TOF
mass spectrometry and the genotypes differ-
entiated on the basis on the mass of each
allele (Figure 2). All the 534 HCM-causing
mutations were analyzed using MassARRAY
Assay Design 3.1 software. The design
process produced 22 assay plexes. All poly-
merase chain reaction (PCR) and iPLEX reac-
tions were performed under standard condi-
tions(14) on a 384-well plate, allowing analysis
of 17 samples against the 22 assay plexes on
the one plate. The multiplex PCR was carried
out using the Complete PCR Reagent Kit
(3840 reactions, Sequenom) in a 5-ml volume
on an ABI 7900 PCR system (Applied
Biosystems). The data were analyzed with
Typer 3.4 and 4.0 software (Sequenom). 
Mutation scanning of all samples was per-
formed using a high-resolution melting (HRM)
technique in a real-time PCR thermal cycler
(LightCycler 480, Roche Diagnostics). The
primers were constructed according to the com-
mon HRM specifications [http://www.gene-
quantification.de/LC480-Technical-Note-01-
HRM.pdf], using the following online software
and databases: UCSC Genome Browser
(http://genome.ucsc.edu/cgi-bin/hgGateway),





The HPLC grade primers were purchased from
Metabion (Germany). The amplification, melting
and fluorescence detection conditions were as
indicated by the supplier (Roche Diagnostics).
Briefly, after amplification (35 cycles of 95 ºC
for 10 seconds, 60 ºC for 15 seconds and 72 ºC
for 10 seconds), the PCR products were heat-
ed to 95 ºC and cooled to 40 ºC (for heterodu-
plex formation), and melting was monitored
(by fluorescence emission) from 65 ºC to 
95 ºC. Table I lists the exon-intron boundaries
covered in the analysis (fragments inclu-
de 100 bp 5’ and 3’ flanking intronic re-
gions). Reference sequences of the genes 
were obtained from the Genome Browser of the
University of California, Santa Cruz
(http://genome.ucsc.edu/cgi-bin/hgGateway).
Results were analyzed independently and when
a mutation or a new variant was found, the PCR
product was purified and sequenced (as a paid
service, Stab Vida, Portugal). 
Whenever a mutation was confirmed in a
proband, first- and second-degree relatives
were tested for the identified variant in order
to check the cosegregation with the disease in
the family. Except for nonsense and frame-
shift mutations, due to short insertions or
deletions and splice site mutations, a mis-
sense variant was considered as a mutation
when: it cosegregated with the disease in the
family; it affected an amino acid conserved
among species and isoforms; and it was not
detected in at least 200 chromosomes of
healthy adult controls. 
RESULTS
iPLEX results
In sample type 1, seven HCM patients
were initially sequenced for the five most
important HCM genes(12) and several muta-
tions were found in two genes, MYBPC3 and
MYH7, as shown in Table II. Importantly, all
these blinded mutations were also detected by
MSG technology (Table II).
In sample type 3, comprising the five HCM
patients not previously genetically studied,
mutations were found by MSG in patients
CMH016, CMH024, CMH030, CA02 (Figures
3, 4, and 5; Table II). In sample type 2, which
includes patient CMH012, negative by AS for
mutations in the five most common HCM
genes, a mutation was detected by MSG (Table
II; Figures 3, 4, and 5). In patient CMH004 we
were only able to detect a polymorphism by
MSG (Table II). Two samples from healthy
individuals (with no HCM disease) were used
as controls in each MSG assay.
Finally, MSG analysis in patient CMH002
(sample type 3) failed to identify any known
HCM mutation.12
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Gene OMIM Reference Protein Exons Known mutations **
sequence * Analyzed (analyzed in
/Total this paper)
MYBPC3 600958 NM_000256 Cardiac myosin-binding 32/32 241 (169)
MYH7 160760 NM_000257 β-cardiac myosin heavy protein chain 40/40 224 (224)
TNNT2 191045 NM_000364 Cardiac troponin T 16/16 37 (32)
TNNI3 191044 NM_000363 Cardiac troponin I 8/8 33 (26)
MYL2 160781 NM_000432 Regulatory myosin light chain 6/7 13 (10)
TPM1 191010 NM_0001018005 α-tropomyosin 9/10 11 (11)
ACTC1 102540 NM_005159 Cardiac actin 6/6 12 (8)
MYL3 160790 NM_000258 Essential myosin light chain 7/7 5 (5)
CSRP3 600824 NM_003476 Muscle LIM protein (MLP) 6/6 7 (7)
TCAP 604488 NM_003673 Telethonin 2/2 5 (5)
TTN 188840 NM_133378 Titin 2/45 9 (2)
TNNC1 191040 NM_003280 Troponin C 6/6 3 (1)
MYH6 160710 NM_002471 α-myosin heavy chain 13/39 5 (2)
MTCYB 516020 AC_000021.2 Cytochrome b of complex III 1/1 2 (2)
MTTG 590035 AC_000021.2 Mitochondrial RNA transfer, glycine 1/1 1 (1)
MTTI 590045 AC_000021.2 Mitochondrial RNA transfer, isoleucine 1/11 (1)
OBSCN 608616 NM_052843 Obscurin 1/52 2 (1)
MYOZ2 605602 NM_016599 Myozenin 2 2/6 2 (2)
MYLK2 606566 NM_033118 Myosin light chain kinase 2 1/12 2 (2)
MYO6 600970 NM_004999 Myosin VI 1/35 1 (1)
DES 125660 NM_001927 Desmin 1/9 1 (1)
FXN 606829 NM_000144 Frataxin 1/5 1 (1)
PRKAG2 602743 NM_016203 y2 subunit of AMP-activated 2/12 9 (7) 
protein kinase 
LAMP2 309060 NM_01399? Lysosome-associated membrane 1/9 1 (1)
protein-2   
RAF1 164760 NM_002880 V-raf-1 murine leukemia viral 1/17 1 (1)
oncogene homolog 1   
CASQ2 114251 NM_001232 Calsequestrin 2 1/11 1 (1)
JPH2 605267 NM_020433 Junctophilin 2 6/6 4 (4)
VCL 193065 NM_014000 Vinculin 1/7 1 (1)
SLC25A4 103220 NM_001151 Solute carrier family 25 member 4 1/4 1 (1)
PLN 172405 NM_002887 Phospholamban 1/2 5 (1)
COX15 603646 NM_078476 Cytochrome C oxidase assembly 1/9 4 (2)
protein 15
CAV3 601253 NM_033337 Caveolin 3 2/2 1 (1)
Table I. Exons and exon/intron boundaries included in the HRM analysis. In bold are the five main HCM-associated genes. The 
number of HCM-associated mutations known** and those analyzed in this work are also indicated. 
* obtained from UCSC Genome Browser (http://genome.ucsc.edu/cgi-bin/hgGateway)
** Human Genome Mutation Database http://www.hgmd.org; and Harvard Sarcomere Gene Protein Mutation Database
http://genepath.med.harvard.edu/~seidman/cg3/
Patient (sample type) Gene (exon) Mutation Detected by MSG
CMH001 (1) MYBPC3 (25) c.2693G>A, p.V896M, Yes
CMH003 (1) MYH7 (23) c.2770G>A, p.E924K Yes
CMH004 MYH7 (32) c.4472C>G, p.Ser1491Cys (rs3729823) Yes
CMH005 (1) MYBPC3 (25) c.2824C>T, p.R943ter Yes
CMH006 (1) MYBPC3 (25) c.2824C>T, p.R943ter Yes
CMH013 (1) MYH7 (9) c.788T>C, p.I263T Yes
CMH014 (1) MYBPC3 (16) c.1727G>A, p.W576ter Yes
CMH035 (1) MYBPC3 (15) c.1502G>A, p.R501Q Yes
CMH012 (2) CSRP3 (3) c.128delC, p.A43Vfs165 Yes
CMH016 (3) TNNT2 (15) c.833A>T; p.N278I Yes
CMH024 (3) MYH7 (9) c.788T>C; p.I263T Yes
CMH030 (3) MYBPC3 (15) c.1465G>A; p.R494Q Yes
CA02 (3) CSRP3 (3) c.128delC, p.A43Vfs165 Yes
Table II. Patients, genes and mutations detected by MSG.
High-resolution melting analysis
The CMH002 sample with no gene alter-
ation detected by MSG was subjected to HRM
covering 32 genes, thee five main HCM-asso-
ciated genes (bold in Table I) and the 27 other
genes with low association with disease (Table
I). HRM primers were designed to prevent the
formation of nonspecific PCR products
(primer dimers, other fragments), fragment
folding, and multiple melting domains. The
performance of the primer pairs was verified
by analysis of the melting temperature peak
(first derivative of the melting curve).
Mutation scanning was only performed in frag-
ments with a unique melting temperature
peak. Of the tested primers, 100% were found
suitable for mutation scanning. The same con-
trol samples used as negative samples for
MSG were used for HRM. The detection of
heteroduplexes was achieved by comparing
the melting profiles, through difference plots
(plots of differences between each point of the
melting profile of the reference samples and
the analyzed sample). If differences were
judged significant, in that they fell outside the
accepted range of variation of the wild-type
samples, they were marked as variants.
Fragments that included variations by this
method were sequenced for confirmation and
4% were found to be false positives. Testing of
fragments with known variants revealed no
false negatives. HRM enabled us to discover a14
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Figure 3. A. Graphical representation of MSG analysis illustrating the c.128delC mutation in the CSRP3 gene. The presence of two peaks
(arrows) indicates the mutation with a heterozygotic allelic pattern in which the masses correspond to the DEL and C alleles, respective-
ly. B. Peak area plot corresponding to the wild-type allele (C) vs. the peak area of the mutated allele (DEL). The blue dots correspond to
samples CMH012 and CA02, both heterozygotes for the c.128delC mutation in the CSRP3 gene. The pink dots correspond to negative
samples referring to the same mutation. 
Figure 4. Chromatograms resulting from sequencing exon 3 of the CSRP3 gene in a healthy control (left) and CMH012 and CA02 patients
(right). 
novel variation within exon 7 of the MYBPC3
gene (NM_000256) (Table III; Figure 5A). 
Automated sequencing of this exon
revealed the presence of a novel mutation,
c.817C>T/p.Arg273Cys, in the MYBPC3 gene
in patient CMH002 (Figure 5B). 
Despite the fact that this mutation is
uncharacterized at the cellular level and has
not been previously reported in the literature,
we were unable to detect it in 200 chromo-
somes obtained from healthy control subjects
(results not shown). 
DISCUSSION AND CONCLUSIONS
There are several genetic causes for left
ventricular hypertrophy, and differential diag-
nosis is important because treatment options
and prognosis may differ. Among these, HCM
is the most frequent cause of SD in otherwise
healthy young people; it may in fact be the
only clinical manifestation of the disease.
Genetic diagnosis is important in all patients
with suspected HCM for several reasons:
counseling on professional and/or leisure
activities (particularly in young people with a
family history or familial SD); for genetic
counseling (in the belief that certain muta-
tions may be more dangerous than others);
and, in general, to facilitate genetic diagnosis
in family members once a mutation has been
identified in the index patient. 
In everyday practice, genetic diagnosis by
standard procedures is difficult since these are
technically complex, time-consuming and
expensive. MSG and HRM have been shown to
be a promising strategy, enabling low-cost,
accurate and rapid diagnosis of HCM. In this
study a novel mutation in the MYBPC3 gene
was identified by combining MSG and HRM.
Using MSG, we were also able to detect a known
mutation, c.128delC (p.Ala43ValfsX165)(7), in
exon 3 of the CSRP3 gene (NM_003476)
(Figures 3 and 4), not detected by current HCM
genetic diagnosis by AS of the five most com-
mon HCM genes. Within the analyzed group
this mutation was detected in two samples from
unrelated individuals (CMH012 and CA02)
(Figures 3 and 4) and its presence was subse-
quently confirmed by AS (Figure 4). The
CMH012 sample had previously been
15
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Figure 5. A. Melting curves of exon 7 of the MYBPC3 gene (NM_000256). The arrow indicates the altered profile indicating a variation
in sample CMH002. B. Difference plot of the melting curves. The arrow indicates a possible variation. Two healthy controls were used
as a reference. C. Sequencing of exon 7 of the MYBPC3 gene (NM_000256). Left – healthy control, Right – HCM patient (CMH002).
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Patient (sample type) Gene (exon) Mutation confirmed by sequencinge
CMH002 (3) MYBPC3 (7) c.817C>T, p.Arg273Cys Yes
Table III. Patient, gene and mutation detected by HRM.
* obtained from UCSC Genome Browser (http://genome.ucsc.edu/cgi-bin/hgGateway)
** Human Genome Mutation Database http://www.hgmd.org; and Harvard Sarcomere Gene Protein Mutation Database
http://genepath.med.harvard.edu/~seidman/cg3/
sequenced for MYBPC3, MYH7, TNNT2,
TNNI3 and MYL2 mutations, with no relevant
sequence alterations. The CA02 sample had
not previously been studied.
Both patients (CMH012, female and
CA02, male) presented sub-aortic obstruction
at rest and septal thickness (measured by
echo) was 25 mm and 23 mm respectively. The
CMH012 patient was followed for 6 years.
Additionally, she had angina pectoris, heart
failure due to ventricular diastolic dysfunction
and syncopal events unrelated to effort or dys-
rhythmia, similarly to the symptoms of the
male patient reported elsewhere(7). The
CMH012 patient died from heart failure at the
age of 50, not long after testing. Her sister is
also clinically affected (mild phenotype with
mild septal hypertrophy), while her daughter
has no ECG or echo criteria for HCM. Despite
our efforts we have not yet been able to geno-
type them. 
We have shown that MSG enabled the
detection of the c.128delC mutation in exon 3
of the CSRP3 gene. The mutation was previ-
ously described as causing HCM in a 53-year-
old male, diagnosed at 46 years of age (7). This
patient was reported to suffer from angina pec-
toris and dyspnea, and also presented pre-
syncope on follow-up (7). Also AS of the five
main sarcomeric genes did not revealed any
HCM-causing mutation for this patient (7). The
c.128delC mutation generates a frame shift
starting at the 43rd codon (out of 195 in the
normal protein), thereby changing the struc-
ture of muscle LIM protein. This changes con-
served regions (figure 6A), including zinc fin-
gers, which are considered important for pro-
tein-protein interaction. These facts are con-
sistent with the hypothesis that this mutation
is the cause of the HCM phenotype. 
In the case of sample CMH002, in which
no mutation was detected using MSG, HRM
was used for mutation scanning in all 32 HCM
genes. This procedure enabled detection of
the c.817C>T/p.Arg273Cys mutation in the
MYBPC3 gene for this patient. To our know-
ledge, there has been no report of this muta-
tion causing HCM. Its absence from the poly-
morphism databases (www.ensembl.org;
www.ncbi.nlm.nih.gov) and from the 200 ana-
lyzed chromosomes excludes it from being a
common variant (results not shown). The con-
servation of this amino acid across mammals
(Figure 6B), the difference between the prop-
erties of the amino acids changed (arginine –
polar, basic; cysteine – acid, non-polar), and
reports of an HCM-causing mutation in the
same codon (16), are all consistent with a dis-
ease-causing mutation. Patient CMH002 (47
years old) was first diagnosed with HCM at the
age of 44 in the course of infectious endo-
carditis of the mitral valve. The ECG was
apparently normal but he had major echo cri-
teria with a septal thickness of 27 mm. His
brother had HCM diagnosed at the age of 28
and there have been three sudden deaths in
their mother’s family (ages <50 years). 
In this work we were able to detect all the
blinded mutations in the tested samples and
also to detect a mutation, c.128delC, in exon 3
of CSRP3, a gene not currently analyzed by
standard HCM genetic testing, in two unrelated
HCM patients, and a novel mutation,
c.817C>T/p.Arg273Cys, in exon 7 of MYBPC3
in another HCM patient. These mutations are
the probable cause of these patients’ HCM
phenotype. Nevertheless, to further character-
ize the biological effect of these mutations in
both genes, family members will be screened
(first- and second-degree relatives with or
without HCM symptoms) and functional stud-
ies using cardiomyocyte cultures harboring
these mutations are currently been performed.
Taken together, these results highlight the
multiplex capacity of the MSG-based array,
with which we were able to screen for 534
known mutations (in 32 genes) in at least 15
HCM patients, and also highlight the ability of
HRM to rapidly scan all coding regions and
intron-exon boundaries of the 32 HCM-asso-
ciated genes to find new variations and proba-
ble disease-causing mutations. High-through-
put coupled MSG-HRM constitutes a strong
candidate tool for fast and accurate diagnosis
in multigenic diseases such as HCM.
However, MSG-based array genotyping is
much less expensive and has a much lower
false positive rate (1%) than HRM, making it
a promising technique when the mutation sta-
tus of a population and the genes involved in
the disease are fully known. 
In this work we aimed to improve our gene-
based diagnostic tools by using two new high-
throughput genotyping technologies. In this
regard, understanding the genetic basis of
HCM in the Portuguese population provides
the opportunity for gene-based diagnosis (17).
The benefits of gene-based diagnosis of HCM
for basic research and for clinical medicine
are limited by the considerable costs of cur-
rent genetic testing strategies and an incom-
plete knowledge of all disease genes. Recent
genetic studies demonstrate variability in the
types of HCM mutations among different pop-
ulations. For example, 4% of the South Asian
(Indian) population carries a common sarcom-
ere protein gene mutation in MYBPC3 that
causes HCM and increases the risk for heart
failure >6-fold (18). In the Netherlands, a sin-
gle founding mutation also accounts for a sub-
stantial percentage of HCM, while in the US,
there is marked genetic heterogeneity and
most HCM patients have a unique pathogenic
mutation (17, 19). The genetic basis for HCM in
Portugal has not yet been extensively studied
(1, 13, 20, our work). Because most HCM
mutations were defined in many different pop-
ulations (http://www.hgmd.org), its suitability
for detecting HCM mutations in Portuguese
population is still unknown, even though we
were able to identify all the blinded muta-
tions. In this regard, and due to the small
number of samples analyzed in this work, we
are currently genotyping more than 100 clini-
cally characterized HCM patients from differ-
ent regions of Portugal with an extended ver-
sion of our MSG array that will be able to
detect 646 mutations in the 32 HCM-associat-
ed genes. Moreover, the number of known
HCM mutations continued to expand; 250
HCM mutations have recently been found by
our collaborators at the Harvard Medical
School in US patients (C.E Seidman and J.
Seidman, personal communication). These 17
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Figure 6. A. Conservation across species of the region between the 40th and 60th amino acid positions of muscle LIM protein (source:
http://www.uniprot.org/). The arrow indicates the first amino acid changed by the CSRP3 c.128delC mutation. (BOVIN – Bos taurus; DANRE –
Danio rerio [zebrafish]; HUMAN – Homo sapiens; MOUSE – Mus musculus; RAT – Rattus norvegicus; XENTR - Silurana tropicalis [western
clawed frog]). B. Conservation across species of a region of myosin-binding protein C (source: http://www.uniprot.org/). The arrow indicates the
first amino acid changed by the mutation (legend as for figure 6A).
mutations and the new mutation detected in
this work will also be added to our MSG-based
array, so as to optimize detection of HCM
mutations in Portuguese patients. 
In conclusion, in this work we have ful-
filled our initial objectives and demonstrated
the diagnostic efficacy of MSG and HRM in
this pathology by studying 13 HCM patients.
We were able to detect all the blinded muta-
tions in the tested samples, a mutation in a
gene (CSRP3) not currently analyzed by stan-
dard HCM genetic testing, and a novel muta-
tion in the MYBPC3 gene. These methodolo-
gies are currently being applied by our group
to a cohort of more than 100 Portuguese HCM
patients.
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